Subscribe To
Verve therapeutics to present at the cowen 42nd annual healthcare conference
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of ...
February 23, 2022, 6:30 am
Medtronic's (mdt) q3 earnings beat, revenues lag estimates
Medtronic (MDT) registers organic growth in the cardiovascular, Neuroscience and Diabetes segments in Q...
February 22, 2022, 12:19 pm
Medtronic's (mdt) q3 earnings beat, revenues lag estimates
Medtronic (MDT) registers organic growth in the cardiovascular, Neuroscience and Diabetes segments in Q...
February 22, 2022, 12:19 pm
Medtronic's (mdt) q3 earnings beat, revenues lag estimates
Medtronic (MDT) registers organic growth in the cardiovascular, Neuroscience and Diabetes segments in Q...
February 22, 2022, 12:19 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...
February 14, 2022, 2:10 pm
Silence therapeutics posts first human data for cardiovascular candidate
Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose. Get the Inside Access Trad...
February 9, 2022, 3:35 pm
Silence therapeutics posts first human data for cardiovascular candidate
Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose. Get the Inside Access Trad...
February 9, 2022, 3:35 pm
Silence therapeutics posts first human data for cardiovascular candidate
Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose. Get the Inside Access Trad...
February 9, 2022, 3:35 pm
Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences
AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a ...
February 3, 2022, 2:24 pm
Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences
AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a ...
February 3, 2022, 2:24 pm
Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences
AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a ...
February 3, 2022, 2:24 pm
cardiovascular systems, inc. (csii) ceo scott ward on q2 2022 results - earnings call transcript
cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript...
February 3, 2022, 2:23 pm
cardiovascular systems, inc. (csii) ceo scott ward on q2 2022 results - earnings call transcript
cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript...
February 3, 2022, 2:23 pm
cardiovascular systems, inc. (csii) ceo scott ward on q2 2022 results - earnings call transcript
cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript...
February 3, 2022, 2:23 pm
Madrigal pharma's kidney disease candidate improves liver, cardiovascular health
Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom. [ALERT] Nic Chahine shares ...
January 31, 2022, 8:46 am
Madrigal pharma's kidney disease candidate improves liver, cardiovascular health
Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom. [ALERT] Nic Chahine shares ...
January 31, 2022, 8:46 am
Madrigal pharma's kidney disease candidate improves liver, cardiovascular health
Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom. [ALERT] Nic Chahine shares ...
January 31, 2022, 8:46 am
Ionis, pfizer scrap plans for experimental cardiovascular drug
Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...
January 31, 2022, 7:41 am